Clinical Trials on Cervical Inflammation and Human Papilloma Virus Performance in Finland

Total 253 results

National Institute of Allergy and Infectious Diseases...

Completed

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

HIV Infections | Hepatitis C | Liver Disease

United States, Puerto Rico
Hologic, Inc.

Completed

Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay (HBVQuant)

Hepatitis B, Chronic

United States, Canada, Germany, Hungary, Turkey, Australia, Bulgaria, Italy, New Zealand, Romania
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection (MINMON)

Liver Diseases | Hepatitis C | HIV-1-infection

United States, Uganda, Brazil, Puerto Rico, South Africa, Thailand
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Chronic Hepatitis C

United States, Germany, Australia, United Kingdom, France, Netherlands, Canada, New Zealand, Italy, Poland, Austria, Estonia, Spain, Sweden, Puerto Rico, Czech Republic
National Institute of Allergy and Infectious Diseases...

Completed

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

HIV Infection | Hepatitis C Infection

United States, Puerto Rico
BioNTech SE
Pfizer

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza

COVID-19 | Influenza, Human

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

Hepatitis C

United States, Canada, Germany, Puerto Rico, Spain
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis

Chronic Hepatitis C Virus

United States, United Kingdom, Canada, Germany, Poland
MDVI, LLC
MediVector, Inc.

Completed

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

Influenza

United States, Russian Federation, Turkey, Spain, Belgium, Hungary, South Africa, Bulgaria, Ukraine, Poland, Netherlands, Australia, New Zealand, Sweden
Hoffmann-La Roche

Completed

A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Belgium, France, Sweden, United States, Romania, United Kingdom, Denmark, Germany, Russian Federation, Canada, Puerto Rico, Hungary, Poland, Netherlands, Brazil
Hoffmann-La Roche

Completed

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
Hoffmann-La Roche

Completed

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

France, Germany, United States, Spain, Canada, Austria, United Kingdom, Puerto Rico, Italy, Brazil, Mexico
SciClone Pharmaceuticals

Completed

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

Hepatitis C | Hepatitis C, Chronic

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Hepatitis C, Chronic

France, Spain, United States, Germany, Canada, Australia, Austria, United Kingdom, Puerto Rico, Italy
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Chronic Genotype 1a or 1b HCV Infection

United States, Canada, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
Hoffmann-La Roche

Completed

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, Germany, United States, Canada, Austria, Puerto Rico
Gilead Sciences

Terminated

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

Hepatitis C Virus Infection

France, Spain, United States, Australia, Canada, Germany, United Kingdom, Italy, New Zealand, Puerto Rico
Debiopharm International SA

Terminated

Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C

Hepatitis C

United States, Germany, France, Spain, Italy, United Kingdom, Puerto Rico, Canada
Hoffmann-La Roche

Completed

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

United States, Spain, France, Canada, Germany, Austria, Australia, Brazil, United Kingdom, Italy, Mexico, Poland, Puerto Rico
Hoffmann-La Roche

Completed

REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy

Hepatitis C, Chronic

Belgium, France, Germany, Italy, Spain, Sweden, United States, Greece, Portugal, Turkey, Switzerland, Canada, United Kingdom, Brazil
Gilead Sciences

Completed

A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response

Hepatitis C, Chronic

United States, Spain, Australia, Netherlands, Italy, New Zealand, Germany, United Kingdom, France, Sweden, Canada, Estonia, Poland, Puerto Rico, Austria, Czechia
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection (ION-2)

Chronic Hepatitis C Virus

United States
BioNTech SE
Pfizer

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

COVID-19 | Influenza

United States
Hoffmann-La Roche

Completed

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Hepatitis C, Chronic

Australia, France, Italy, Spain, United States, Canada, Germany, Puerto Rico, New Zealand
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Hepatitis C

Argentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
Gilead Sciences

Completed

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (NEUTRINO)

Chronic Hepatitis C

United States, Puerto Rico
MDVI, LLC
MediVector, Inc.

Completed

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults

Influenza

United States, Canada, Brazil, Mexico, Colombia, Argentina, Peru, Puerto Rico, Guatemala, Dominican Republic, El Salvador
GlaxoSmithKline

Completed

Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery

Hepatitis B | Tetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type b | Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines

Finland, Australia, Spain, Italy, Canada, Czechia
GlaxoSmithKline

Completed

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Neisseria Meningitidis | Haemophilus Influenzae Type b

United States, Australia, Mexico
Hoffmann-La Roche

Terminated

An Observational Study on Long-Term Persistence of Resistant Mutations And Durability of Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Direct Acting Antiviral (DAA)- Containing Regimens

Hepatitis C, Chronic

France, United States, Canada, New Zealand, Spain, Germany, United Kingdom, Australia, Italy, Brazil, Mexico, Slovakia, Poland, Puerto Rico, Austria
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon (POSITRON)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico, Australia
Gilead Sciences

Completed

Gilead Sustained Virologic Response (SVR) Registry

Hepatitis C, Chronic

United States, Spain, Netherlands, France, Australia, Canada, Italy, Germany, New Zealand, Belgium, Sweden, United Kingdom, Estonia, Puerto Rico, Austria, Poland, Czechia
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; National Heart, Lung, and Blood... and other collaborators

Completed

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)

Myocardial Infarction | Heart Failure

United States, Canada, Puerto Rico
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Bristol-Myers Squibb

Completed

Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection (COMMAND-3)

Hepatitis C

Australia, France, Germany, Italy, United Kingdom, United States, Canada, Poland, Austria, Denmark, Israel, Spain, Russian Federation, Switzerland, Argentina, Brazil
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Chronic Hepatitis C Infection

United States, Spain, United Kingdom, Canada, Germany, France, Austria, Poland, Belgium, Czech Republic, Italy
BioCryst Pharmaceuticals
Department of Health and Human Services

Completed

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

Fatigue | Myalgia | Cough | Headache | Nasal Congestion | Seasonal Influenza | Sore Throat

United States, Mexico, Canada, Australia, New Zealand, Puerto Rico
BioCryst Pharmaceuticals
Department of Health and Human Services

Terminated

A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza

Cough | Fever | Headache | Nasal Congestion | Seasonal Influenza | Sore Throat

United States, Poland, Ukraine, Germany, Belgium, Argentina, Israel, Bulgaria, Serbia, South Africa, Brazil, Canada, Chile, Peru, Russian Federation, Hungary, Czech Republic, India, United Kingdom, Latvia, Bosnia and Herzegovina, ... and more
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Haemophilus Influenzae Type b Immunisation | Polio Immunisation | Measles Immunisation | Rubella Immunisation | Varicella Immunisation | Mumps Immunisation

United States, Canada, Honduras, Puerto Rico
Rigshospitalet, Denmark
University College, London

Enrolling by invitation

EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV (EuroSIDA)

End Stage Liver Disease | Cardiovascular Diseases | Fractures, Bone | Diabetes Mellitus | Renal Insufficiency | Hepatitis B | Hepatitis C | Kidney Failure, Chronic | Proteinuria | HIV | Coinfection | Acidosis, Lactic | AIDS

Spain, Switzerland, Germany, United Kingdom, Austria, Sweden, Finland, Israel, Denmark, France, Italy, Iceland, Belgium, Slovakia, Norway, Lithuania, Portugal, Poland, Croatia, Czechia, Greece, Hungary, Luxembourg, Argentina, Belarus, Bosnia... and more
Incyte Corporation

Active, not recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions

Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway

Clinical Trials on Cervical Inflammation and Human Papilloma Virus Performance in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations